Bright Peak Immunoconjugates – A New Class Of Multi-Functional Biologics
Time: 1:30 pm
day: Day Two
Details:
- Overviewing Bright Peak’s immunoconjugate platform, designed to upgrade immune checkpoint therapy to the next level
- An update on BPT567 as the first PD1-IL18 immunoconjugate to enter the clinic
- Exploring the opportunity for novel biologic activity via Cis signaling with enhanced efficacy and safety
